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From: Medical Conspiracy Theories and Health Behaviors in the United States
JAMA Intern Med. 2014;():. doi:10.1001/jamainternmed.2014.190

Vaccine Attitudes, Concerns, and Information Sources
Reported by Parents of Young Children: Results from the 2009
HealthStyles Survey
Kennedy, Basket, & Sheedy. Pediatrics 127(S1): S92-99 (2011)

93.4% Reported children receiving vaccine
79.8% Believed vaccines important to child health
79.0% Confident about vaccine safety

Effective Messages in Vaccine Promotion: A Randomized Trial
Nyhan et al., Pediatrics 133(4): 1-8 (2014)

Tested 4 interventions:
• Lack of evidence for autism link
• Disease dangers
• Disease images
• Dramatic narrative

“decreased intent to vaccinate
among parents who had the
least favorable vaccine
attitudes”

From Nature 473:436 (2011)

21st Century Prophylaxis
• Vaccine
• Manufacturing
• Vaccination
• Host Response
• Preparedness

Vaccine Directions
• Antigen discovery and selection (including in silico)
• Common epitope approaches (universal vaccines)
• Targeting organisms for which drug resistance is emerging
• Novel vaccine concepts to address chronic infectious diseases
• Passive vaccination approaches

Manufacturing Directions
• Unique and diverse expression systems (beyond an egg and
free living organisms)
– Bacteria
– Eukaryotic cells
– Baculo- / insect lines
– Plants
– Synthetic / Cell free translation

• Disposable, large scale platforms
• Synthetic generation of agent

Vaccination Directions
• Adjuvants

– Reduce number of doses
– Reduce antigen load
– Fine tune immune response

• Stabilization

– Eliminate refrigeration requirement
– Enhance shelf life
– Enable novel packaging and devices

• Alternative delivery devices

– Reduce trained health care worker need
– Increase compliance
– Improve throughput

Host Response Directions
• Murine immune system is at best a very crude model of human
immunity (concomitantly, murine pathogenesis is an even
cruder approximation of human disease)
• Animal models are focusing on identification of correlates and
even true immunological surrogates
• Immunity is more than neutralizing antisera
• Improved assessment tools for human immune status and
responses

Ancillary Issues
• Discovery, characterization, and validation of biomarkers for
immune status
• Clinical endpoints
• Robust, reproducible cellular assays
• In vitro / ex vivo predictive systems
• Utilization of “correlates” versus “a correlate”

Erica Saphire, Scripps Research Institute

Selected efforts underway:
•
•
•
•
•
•
•

Characterize virus
Improve diagnostic specificity
Test antivirals
Develop animal models
Natural history studies
Evaluate the Zika & dengue interface
Develop vaccine

Preparedness
• Emerging infectious diseases present unique challenges
• Surveillance systems are crude and limited
• Conduct of research is difficult even under optimal conditions
• Existing regulatory frameworks are not optimal for outbreaks

What do we need to prepare for?
(with apologies to Donald Rumsfeld)

• Expected knowns
– Pandemic Influenza

• Unexpected knowns
– Ebola (or any filovirus)

• Unknown knowns
– Zika

• Unknown unknowns
– ???

Expected knowns (flu)
• History suggests this can and will occur
• Experience with similar vaccines allows for straightforward
(although not necessarily simple or easy) vaccine development
in a timeline that can potentially align with the outbreak
• Existing infrastructure can be co-opted for development
• Safety will always be an issue
– Dose and regimen
– Special populations

Unexpected knowns (Ebola)
• Even with extensive microbiological and pathogenesis
information, socioeconomic / cultural factors can dramatically
impact disease transmission and severity
• New clinical experience may alter prevention & treatment
• Exogenous factors such as climate change, urban versus rural
population centers, greater local and distant mobility, varying
degrees of public health infrastructure, etc.
• Variable degrees of development efforts will need increased
resources and streamlining

Unknown knowns (Zika)
• Extremely difficult to be prepared, mostly due to a long list of
agents that have been identified with higher priority
• Need to rely on expert panels to identify candidate lists
(pandemic / epidemic wanna-be’s)
• Likely need to be already working on vaccine candidates to
impact future outbreaks
• Pandemic / epidemic potential may evolve to endemic
• Resource limitations major impediment

For Consideration
• WHO Workshop on Prioritization of Pathogens (12/8-9/2015)
– Urgent
•
•
•
•
•
•

Crimean-Congo hemorrhagic fever
Filoviruses (EVD & Marburg)
Highly pathogenic emerging Coronaviruses (MERS Co-V & SARS)
Lassa Fever
Nipah
Rift Valley Fever

– Serious

• Chikungunya
• Severe Fever with Thrombocytopenia Syndrome
• Zika

So what’s an unknown unknown?
•
•
•
•
•
•

Basically, something we’ve never seen before
Little precedence with known infectious agents
No information regarding natural immunity
Sparse human pathogenesis
Limited information from animal models
Initially, mostly sequence information

• How can we be prepared?

Zombie Threat Summary
• Pathogenic zombies (PZ)

• PZs are zombie life forms created after an
organism is infected by a virus or bacteria or
some other form of contagion

•
•
•
•
•
•
•

Radiation zombies
Evil Magic zombies
Space zombies
Weaponized zombies
Symbiant-Induced zombies
Vegetarian zombies
Chicken zombies

Moving Faster
• Initiate early development on experts’ derived lists
• Don’t wait for specimens; work from sequences
• Platform selection for ease of candidate selection & manufacturing
– Several vaccine manufacturers are offering proposals

• Move towards universal / broadly protective responses
• Rate limiting issues:
–
–
–
–

Sequence breadth
Animal models
Assay development
Clinical trial capacity in theater

Possible additional considerations
• Broad spectrum antivirals
• Passive vaccination / prophylaxis

Questions?

